PEDIATRICS Vol. 65 No. 3 March 1980, pp. 562-566
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kirkland, R. T.
Right arrow Articles by Clayton, G. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kirkland, R. T.
Right arrow Articles by Clayton, G. W.

Results of Four Years of Intermittent Human Growth Hormone (hGH) and Fluoxymesterone Therapy in Hypopituitary Dwarfism

Rebecca T. Kirkland MD1, R. B. Harrist PhD1, and George W. Clayton MD1

1 Department of Pediatrics, Endocrinology Section, Baylor College of Medicine, and University of Texas, School of Public Health, Houston

In order to investigate the synergistic effect on growth of human growth hormone (hGH) and an anabolic agent, fluoxymesterone, 28 children with hypopituitarism received the combined therapy in an intermittent regimen for one to four years. Fourteen of the children had received prior therapy with growth hormone alone. All of the children were prepubertal. They had a mean chronologic age (CA) of 9.53 years ± 2.33 SD and mean bone age (BA) of 6.05 years ± 2.07 SD. The change in BA/change in height age (HA) le1 in 15 of the 28 children (53.6%). The change in HA/change in CA was ge1 in 17 of 28 (60.7%). The 14 children who had received hGH therapy alone, group A, had a growth velocity of 4.72 cm/yr ± 1.24 SD in the year prior to the combined treatment. This did not differ significantly from the average growth velocity of 5.58 cm ± 1.47 SD during the first year of combined therapy. The average growth velocity of the remaining 14 children, group B, during the first year of combined therapy was 6.72 cm/yr ± 1.01 SD. This differed significantly from the growth velocity of group A before combined therapy (P < .001) and also during the first year of combined therapy (P < .025). The overall mean growth rate in the second year, 5.33 cm, was less than that of the first year, P < .025, and was not different from that achieved with hGH alone. Furthermore, the velocity in each of the following years was similar to that of the second year. The use of intermittent combined therapy in the doses employed in this study does not appear to be of benefit in prolonging catch-up growth in hypopituitary patients. This regimen provides acceleration of growth in the initial year of therapy for those children who have not received prior hGH therapy.

Submitted on January 26, 1979
Accepted on July 10, 1979




This article has been cited by other articles:


Home page
 Am J Sports MedHome page
I. K. Triantafillopoulos, A. J. Banes, K. F. Bowman Jr, M. Maloney, W. E. Garrett Jr, and S. G. Karas
Nandrolone Decanoate and Load Increase Remodeling and Strength in Human Supraspinatus Bioartificial Tendons
Am. J. Sports Med., June 1, 2004; 32(4): 934 - 943.
[Abstract] [Full Text] [PDF]